KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Common Equity (2016 - 2025)

Idexx Laboratories has reported Common Equity over the past 17 years, most recently at $1.6 billion for Q4 2025.

  • Quarterly results put Common Equity at $1.6 billion for Q4 2025, up 0.63% from a year ago — trailing twelve months through Dec 2025 was $1.6 billion (up 0.63% YoY), and the annual figure for FY2025 was $1.6 billion, up 0.63%.
  • Common Equity for Q4 2025 was $1.6 billion at Idexx Laboratories, up from $1.6 billion in the prior quarter.
  • Over the last five years, Common Equity for IDXX hit a ceiling of $1.6 billion in Q3 2024 and a floor of $457.0 million in Q2 2022.
  • Median Common Equity over the past 5 years was $1.2 billion (2023), compared with a mean of $1.1 billion.
  • Biggest five-year swings in Common Equity: surged 551.0% in 2021 and later tumbled 38.92% in 2022.
  • Idexx Laboratories' Common Equity stood at $690.0 million in 2021, then dropped by 11.78% to $608.7 million in 2022, then soared by 143.87% to $1.5 billion in 2023, then grew by 7.46% to $1.6 billion in 2024, then grew by 0.63% to $1.6 billion in 2025.
  • The last three reported values for Common Equity were $1.6 billion (Q4 2025), $1.6 billion (Q3 2025), and $1.5 billion (Q2 2025) per Business Quant data.